ClearPoint Neuro Inc vs Rockwell Automation — how do they compare? ClearPoint Neuro Inc trades at $14.52 (market cap $454.21M), while Rockwell Automation trades at $447.01 (market cap $49.64B). The key difference: Rockwell Automation is far larger — about 109.3× ClearPoint Neuro Inc's market cap, and Rockwell Automation pays a 1.23% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | ROK | |
|---|---|---|
Market Cap | $454.21M | $49.64B |
Sector | Health | Industrials |
52-Week High | $29.60 | $495.08 |
52-Week Low | $8.66 | $333.75 |
Enterprise Value | $488.79M | $52.77B |
Dividend Yield | — | 1.23% |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Rockwell Automation (ROK) trades at $435.22, down 1.32% with a bearish technical signal. The company shows strong earnings momentum with three consecutive quarterly beats and raised 2026 guidance. Valuation metrics appear elevated with P/E of 41.85 and P/S of 5.6, while profitability remains solid with 13.38% net margin. Recent AI integration initiatives and institutional buying activity provide positive catalysts.
ROK presents a mixed outlook with strong operational performance offset by premium valuation. The 16.5% upside to consensus price target of $507 offers potential, but inflation pressures and competitive threats require monitoring. Current technical weakness near support at $432 creates a critical juncture for near-term direction.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →